Targeting a systolic blood pressure below 130 mm Hg was associated with a 21% decreased risk of all-cause mortality among patients with stage 3 to 4 chronic kidney disease, a meta-analysis found.
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
In a study, IgA nephropathy patients lived a median 6 fewer years than age-matched controls without the disease.
In a study of patients with non-dialysis CKD, pruritus was associated with poor health-related quality-of-life.
A combination of intravenous lidocaine and ketorolac was found to be superior to IV lidocaine alone and comparable with IV ketorolac alone for alleviating suspected renal colic pain.
Over 12 weeks, 59% of patients taking the hydrochloric acid binder achieved an increase or normalization in serum bicarbonate.
For nondiabetic CKD patients taking statins, targeting an intensive SBP goal of less than 120 mm significantly reduced the risks for all-cause and cardiovascular mortality by 56% and 71%, respectively, study finds.
Meta-analysis reveals that patients with CKD and ESRD who have hypomagnesemia have a 32% higher risk for death from any cause.
Novel composite score is also reliable single-score summary of Kidney Disease Quality of Life-36
The presence of periodontal disease in chronic kidney disease significantly increased the risk of all-cause, but not cardiovascular, mortality.